Patient profiles and the reactivity of their autoantibodies with mutant GPIIb-IIIa
Patient no. . | Age (y) . | Sex (M/F) . | Plt count (× 103/μL) . | ΔOD* for WT . | ΔOD ratio† [KO/WT] (%) . | ΔOD ratio†[CAM/WT] (%) . |
---|---|---|---|---|---|---|
1 | 40 | F | 23 | 1.287 | 33.4 | 101.7 |
2 | 45 | M | 53 | 1.152 | 98.0 | 97.2 |
3 | 73 | F | 81 | 1.148 | 6.5 | 99.0 |
4 | 43 | F | 28 | 1.003 | 45.9 | 89.2 |
5 | 49 | M | 39 | 1.001 | 92.4 | ND |
6 | 47 | F | 96 | 0.981 | 30.0 | 97.2 |
7 | 56 | F | 43 | 0.968 | 94.0 | 94.8 |
8 | 41 | M | 42 | 0.894 | 45.9 | 100.8 |
9 | 35 | F | 18 | 0.859 | 18.6 | 89.6 |
10 | 35 | F | 43 | 0.815 | 111.9 | ND |
11 | 32 | F | 65 | 0.806 | 107.6 | ND |
12 | 53 | F | 12 | 0.719 | 92.4 | 99.4 |
13 | 49 | F | 64 | 0.680 | 45.5 | 91.7 |
14 | 51 | F | 51 | 0.665 | 90.1 | 84.3 |
15 | 28 | F | 84 | 0.619 | 89.7 | ND |
16 | 32 | F | 55 | 0.565 | 92.4 | ND |
17 | 57 | F | 20 | 0.554 | 87.4 | ND |
18 | 77 | F | 34 | 0.551 | 72.4 | 91.3 |
19 | 67 | F | 37 | 0.476 | 23.7 | 124.0 |
20 | 69 | F | 106 | 0.432 | 71.1 | ND |
21 | 62 | M | 34 | 0.424 | 101.9 | ND |
22 | 30 | F | 66 | 0.392 | 80.4 | 87.7 |
23 | 34 | F | 42 | 0.330 | 128.9 | ND |
24 | 80 | F | 17 | 0.281 | 42.0 | 117.6 |
25 | 77 | F | 27 | 0.270 | 38.9 | 87.7 |
26 | 59 | F | 29 | 0.232 | 87.9 | 96.3 |
27 | 51 | F | 76 | 0.205 | 99.5 | 116.9 |
28 | 61 | M | 60 | 0.196 | 114.8 | ND |
29 | 72 | F | 77 | 0.184 | 123.4 | 111.9 |
30 | 58 | F | 34 | 0.162 | 76.5 | ND |
31 | 62 | F | 50 | 0.160 | 72.5 | 88.0 |
32 | 60 | F | 17 | 0.148 | 41.9 | 125.6 |
33 | 50 | F | 23 | 0.147 | 84.3 | ND |
34 | 55 | F | 26 | 0.088 | 73.8 | ND |
Patient no. . | Age (y) . | Sex (M/F) . | Plt count (× 103/μL) . | ΔOD* for WT . | ΔOD ratio† [KO/WT] (%) . | ΔOD ratio†[CAM/WT] (%) . |
---|---|---|---|---|---|---|
1 | 40 | F | 23 | 1.287 | 33.4 | 101.7 |
2 | 45 | M | 53 | 1.152 | 98.0 | 97.2 |
3 | 73 | F | 81 | 1.148 | 6.5 | 99.0 |
4 | 43 | F | 28 | 1.003 | 45.9 | 89.2 |
5 | 49 | M | 39 | 1.001 | 92.4 | ND |
6 | 47 | F | 96 | 0.981 | 30.0 | 97.2 |
7 | 56 | F | 43 | 0.968 | 94.0 | 94.8 |
8 | 41 | M | 42 | 0.894 | 45.9 | 100.8 |
9 | 35 | F | 18 | 0.859 | 18.6 | 89.6 |
10 | 35 | F | 43 | 0.815 | 111.9 | ND |
11 | 32 | F | 65 | 0.806 | 107.6 | ND |
12 | 53 | F | 12 | 0.719 | 92.4 | 99.4 |
13 | 49 | F | 64 | 0.680 | 45.5 | 91.7 |
14 | 51 | F | 51 | 0.665 | 90.1 | 84.3 |
15 | 28 | F | 84 | 0.619 | 89.7 | ND |
16 | 32 | F | 55 | 0.565 | 92.4 | ND |
17 | 57 | F | 20 | 0.554 | 87.4 | ND |
18 | 77 | F | 34 | 0.551 | 72.4 | 91.3 |
19 | 67 | F | 37 | 0.476 | 23.7 | 124.0 |
20 | 69 | F | 106 | 0.432 | 71.1 | ND |
21 | 62 | M | 34 | 0.424 | 101.9 | ND |
22 | 30 | F | 66 | 0.392 | 80.4 | 87.7 |
23 | 34 | F | 42 | 0.330 | 128.9 | ND |
24 | 80 | F | 17 | 0.281 | 42.0 | 117.6 |
25 | 77 | F | 27 | 0.270 | 38.9 | 87.7 |
26 | 59 | F | 29 | 0.232 | 87.9 | 96.3 |
27 | 51 | F | 76 | 0.205 | 99.5 | 116.9 |
28 | 61 | M | 60 | 0.196 | 114.8 | ND |
29 | 72 | F | 77 | 0.184 | 123.4 | 111.9 |
30 | 58 | F | 34 | 0.162 | 76.5 | ND |
31 | 62 | F | 50 | 0.160 | 72.5 | 88.0 |
32 | 60 | F | 17 | 0.148 | 41.9 | 125.6 |
33 | 50 | F | 23 | 0.147 | 84.3 | ND |
34 | 55 | F | 26 | 0.088 | 73.8 | ND |
ΔOD ratios less than 50% are underlined.
Plt indicates platelet; WT, wild-type GPIIb-IIIa; KO, KO-variant GPIIb-IIIa; CAM, CAM variant GPIIb-IIIa; ND, not done.
[Optical density (OD) value obtained from a test sample] − [(mean + 3 SD) OD value obtained from 5 control samples] in antigen-capture ELISA.
[(ΔOD in antigen-capture ELISA using mutant GPIIb-IIIa)/(ΔOD in antigen-capture ELISA using WT)] × 100.